Development of Candida albicans colitis in a child undergoing steroid therapy for ulcerative colitis.

Ulcerative colitis (UC) is a chronic idiopathic inflammatory bowel disease (IBD) characterized by colonic mucosal inflammation with a relapsing/remitting course. The primary treatment of mild to moderate active UC is sulfasalazine or mesalazine (5-ASA), and the secondary therapy for more severe dise

[1]  A. Dursun,et al.  Detection ofCandida albicans by culture, serology and PCR in clinical specimens from patients with ulcerative colitis: Re-evaluation of an old hypothesis with a new perspective , 2008, Folia Microbiologica.

[2]  W. Sandborn,et al.  Inflammatory bowel disease: clinical aspects and established and evolving therapies , 2007, The Lancet.

[3]  M. Zwolinska-Wcislo,et al.  [The influence of Candida albicans on the course of ulcerative colitis]. , 2006, Przeglad lekarski.

[4]  Toshiaki Shimizu,et al.  Guidelines for treatment of ulcerative colitis in children , 2004, Nihon rinsho. Japanese journal of clinical medicine.

[5]  Robert Feketv.  Guidelines for the Diagnosis and Management of Clostridium dfficile-Associated Diarrhea and Colitis , 2005 .

[6]  L. Samaranayake,et al.  Inhalational and topical steroids, and oral candidosis: a mini review. , 2001, Oral diseases.

[7]  L. Uscanga,et al.  Toxic pseudomembranous colitis in a patient with ulcerative colitis. , 2000, Inflammatory bowel diseases.

[8]  R. Fekety.  Guidelines for the diagnosis and management of Clostridium difficile-associated diarrhea and colitis. American College of Gastroenterology, Practice Parameters Committee. , 1997, The American journal of gastroenterology.

[9]  A. Barkun,et al.  Toxic megacolon complicating pseudomembranous enterocolitis , 1995, Diseases of the colon and rectum.

[10]  S. Shah,et al.  Pseudomembranous colitis in children. , 1986, Indian pediatrics.

[11]  R. Brettle,et al.  Clostridium difficile-associated diarrhoea. , 1984, The Journal of infection.

[12]  Y. Trnka,et al.  Association of Clostridium difficile toxin with symptomatic relapse of chronic inflammatory bowel disease. , 1981, Gastroenterology.

[13]  H. Novey,et al.  Incidence of fungal precipitins in patients treated with beclomethasone dipropionate aerosol. , 1981, Annals of allergy.

[14]  E. Bottone,et al.  Occurrence of Clostridium difficile toxin during the course of inflammatory bowel disease. , 1981, Gastroenterology.

[15]  A. Read,et al.  CLOSTRIDIUM DIFFICILE ASSOCIATED DIARRHŒA: A ROLE IN INFLAMMATORY BOWEL DISEASE? , 1980, The Lancet.

[16]  Y. Trnka,et al.  THERAPEUTIC IMPLICATIONS OF CLOSTRIDIUM DIFFICILE TOXIN DURING RELAPSE OF CHRONIC INFLAMMATORY BOWEL DISEASE , 1980, The Lancet.

[17]  L. Montes,et al.  Oral Candidiasis , 1978, Journal of cutaneous pathology.

[18]  J. Melby.  Drug spotlight program: systemic corticosteroid therapy: pharmacology and endocrinologic considerations. , 1974, Annals of internal medicine.

[19]  G. Crompton,et al.  Beclomethasone Dipropionate and Oropharyngeal Candidiasis , 1974, British medical journal.

[20]  J. Crooks,et al.  THE FAMILY DOCTOR IN THE CONTEXT OF BRITAIN'S SOCIAL SERVICES. , 1965, Lancet.

[21]  M. Catterall,et al.  Results of respiratory-function tests in miners. , 1965, Lancet.